Treatment

Maintenance treatment with the PARP inhibitor rucaparib (Rubraca) greatly improved progression-free survival in patients with recurrent or metastatic endometrial cancer after first- or second-line chemotherapy, according to a phase 2 study. Patients receiving rucaparib had a median progression-free survival of 28.1 months compared with 8.7 months for those given a placebo, representing a 55% lower […]

Abemaciclib Shows High Efficacy in Kaposi Sarcoma, Including HIV-Associated Cases A phase 1/2 trial (NCT04941274) presented at the 2025 ASCO Annual Meeting found that the CDK4/6 inhibitor abemaciclib (Verzenio) was well-tolerated and demonstrated strong antitumor activity in both HIV-associated and HIV-negative Kaposi sarcoma. Among 31 efficacy-evaluable patients, the overall response rate (ORR) was 84%. Patients

Cancer arises from uncontrolled cell growth and genomic instability, often due to defective checkpoints and DNA repair mechanisms. Claspin is a key regulator in this process, acting as a scaffold protein that activates the ATR-Chk1 checkpoint in response to DNA damage or replication stress. By pausing the cell cycle, Claspin allows DNA repair or triggers

A phase 1/2 trial evaluating IDE397, a MAT2A inhibitor, combined with sacituzumab govitecan-hziy (Trodelvy) shows encouraging activity in late-line MTAP-deletion urothelial cancer. Two expansion cohorts were assessed. Dose Level 1 (IDE397 15 mg + Trodelvy 10 mg/kg, n=9) achieved a 33% objective response rate (ORR) and 100% disease control rate (DCR). Dose Level 2 (IDE397

Endometrial cancer, the second most common gynecologic malignancy, is typically treated with carboplatin and paclitaxel, but outcomes remain poor. The Phase 3 RUBY trial evaluated adding the anti–PD-1 drug dostarlimab to this regimen in 494 patients with newly diagnosed advanced or recurrent disease. Dostarlimab significantly improved results: in patients with mismatch repair–deficient or MSI-high tumors,

A new study from University of Chicago, published in Cell Reports Medicine, suggests that zeaxanthin, a plant carotenoid known for eye health, may also boost the immune system’s ability to fight cancer. The compound enhances CD8+ T cells, the body’s tumor-killing immune cells, by stabilizing their T-cell receptor (TCR) complex, leading to stronger activation and

Gastroesophageal cancers, though relatively uncommon in the U.S., cause significant morbidity and mortality worldwide. For early-stage gastric and gastroesophageal junction (GEJ) adenocarcinoma, the primary goal is cure, achieved through multimodality treatment. Landmark trials demonstrated the benefits of perioperative chemotherapy, such as the MAGIC trial’s pECF regimen, and neoadjuvant chemoradiotherapy, like the CROSS trial’s nCROSS regimen.

The COAST trial, a randomized phase 2 study, evaluated whether adding novel immunotherapies to durvalumab could improve outcomes for patients with unresectable stage III non–small cell lung cancer (NSCLC) who had completed chemoradiotherapy without progression. Patients received durvalumab alone, durvalumab plus oleclumab (anti-CD73), or durvalumab plus monalizumab (anti-NKG2A). Updated results showed enhanced activity with both

Prostate cancer treatment has advanced significantly, with approaches tailored to disease stage. For localized or early-stage disease, focal therapies aim to destroy only the cancerous area while sparing healthy tissue, reducing side effects like incontinence and erectile dysfunction. Techniques include high-intensity focused ultrasound (HIFU), cryotherapy, and radiofrequency ablation. Advanced radiation methods, such as intensity-modulated radiation therapy

Recent advances in ovarian cancer treatment are moving toward personalized and targeted therapies, improving outcomes for advanced or recurrent disease. Targeted drugs like PARP inhibitors (e.g., olaparib, niraparib) exploit DNA repair defects in tumors with BRCA mutations or homologous recombination deficiency, often as maintenance therapy after chemotherapy. Angiogenesis inhibitors, such as bevacizumab, block tumor blood